Olsson G, Rehnqvist N
Department of Medicine, Karolinska Institutet, Danderyd Hospital, Sweden.
Cardiology. 1987;74(6):457-64. doi: 10.1159/000174238.
In a double-blind randomized study of 154 postmyocardial infarction patients assigned to metoprolol (100 mg twice daily) and 147 patients assigned placebo, the outcome during a 3-year follow-up according to serum cholesterol concentrations was evaluated. There was no indication that metoprolol influenced the total serum cholesterol concentration. The median cholesterol value at 3 months was 6.7 mmol/l. In patients with cholesterol less than or equal to 6.7 mmol/l, nonfatal reinfarctions were reduced in the metoprolol group (7 vs. 24%; p less than 0.01). In patients with cholesterol greater than 6.7 mmol/l, mortality was lower in those treated with metoprolol (8 vs. 20%; p less than 0.05). The beneficial effect of conventional postinfarction beta-blockade with metoprolol is independent of serum cholesterol concentration.
在一项针对154例心肌梗死后患者（分配接受美托洛尔治疗，每日两次，每次100毫克）和147例分配接受安慰剂治疗的患者的双盲随机研究中，根据血清胆固醇浓度评估了3年随访期间的结果。没有迹象表明美托洛尔会影响总血清胆固醇浓度。3个月时胆固醇的中位数为6.7毫摩尔/升。在胆固醇小于或等于6.7毫摩尔/升的患者中，美托洛尔组的非致命性再梗死有所减少（7%对24%；p<0.01）。在胆固醇大于6.7毫摩尔/升的患者中，接受美托洛尔治疗的患者死亡率较低（8%对20%；p<0.05）。心肌梗死后常规使用美托洛尔进行β受体阻滞剂治疗的有益效果与血清胆固醇浓度无关。
